Only 58% of FDA-licensed therapies reach Europe in a comparable timeline. But for patients, every day counts. This report looks into the 67-day process from the final opinion of the Committee for Medicinal Products for Human Use (CHMP) to the final decision of the European Commission and recommends three solutions to improve patient access.